Please login to the form below

psoriatic arthritis

This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as studies in psoriatic arthritis and atopic dermatitis ... Novartis’ drug is currently approved for adults with

Latest news

J&J splashes $750m on anti-inflammatory drug bermekimab

J&J is already a leader in the immunology market, and recently filed its next-generation IL-23 inhibitor Tremfya in psoriatic arthritis (PsA) with the European Medicines Agency.
Amgen raises forecasts after closing $13.4bn Otezla deal

Otezla grew 26% to reach $1.6bn in sales across its psoriasis, psoriatic arthritis and Behçet's disease indications last year, and has continued its expansion this year with a tally
Novartis’ Cosentyx misses the mark in Humira head-to-head

Narrowly missed statistical significance for superiority. Novartis’ Cosentyx (secukinumab) failed to show significant superiority over AbbVie’s Humira (adalimumab) in a head-to-head trial in psoriatic arthritis (PsA). ... We will assess the EXCEED
Pfizer raises forecast following growth of biopharma business

Aside from its oncology business, Pfizer also saw growth of its global revenues for Xeljanz to $599m due to continued volume growth in the rheumatoid arthritis indication and the recent launch ... for psoriatic arthritis in the US.
Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis. Johnson &Johnson’s Janssen division has filed its immunology therapy Tremfya for psoriatic arthritis (PsA) in Europe, hoping to extend use of the drug

More from news
Approximately 15 fully matching, plus 120 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular
Drug launches to watch in 2019

Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.
The good, the bad and the ugly

Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic
Deal Watch December 2016

510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small
Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Changing healthcare, one film at a time

Millefeuille’ [ IMDB] explores the issues of isolation and restriction people with psoriasis and psoriatic arthritis struggle with, and the degree to which they are self-imposed, through the character of Élodie –
emotive adds to medical team with new Scientific Lead and Associate Medical Writer

Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
Lucid win PMEA Support Agency of the Year 2016

management of psoriatic arthritis.Judges’ comments: “In taking a different approach, this work stands out from the many support programmes already out there.
Lucid make the shortlist in all of the four categories they entered for the PMEA programme 2016

um: Changing clinical behaviour on a global scale to improve standards of care in the management of psoriatic arthritis. .
Millefeuille

This story of hope charts Élodie’s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. This story of hope charts Élodie’s physical and mental struggles

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....